Matches in SemOpenAlex for { <https://semopenalex.org/work/W1905903151> ?p ?o ?g. }
- W1905903151 endingPage "E726" @default.
- W1905903151 startingPage "E721" @default.
- W1905903151 abstract "Study Type – Therapy (phase 1) Level of Evidence 2a What's known on the subject? and What does the study add? High-risk and locally advanced prostate cancers are difficult to cure with the standard regimen of radiation therapy (RT) with concurrent androgen-deprivation therapy (ADT). Multiple studies have explored the addition of docetaxel chemotherapy in attempt to improve patient outcomes. Prior Phase I studies have shown that docetaxel 20 mg/m2 is a safe dose, when given concurrently with 70 Gy of radiation. But current standard RT for prostate cancer uses higher doses, and it is unclear if concurrent chemotherapy is safe with modern RT. This is a Phase I study that explored the addition of concurrent docetaxel chemotherapy to modern RT (intensity-modulated RT to 78 Gy) plus ADT. The study showed that weekly docetaxel at 20 mg/m2 is safe with modern RT. At a median follow-up of 2.2 years, biochemical progression-free survival was 94%. This triple-therapy regimen is safe and promising for further evaluation in prospective trials. OBJECTIVE • To evaluate in a phase I trial, the feasibility of adding concurrent weekly docetaxel chemotherapy to high-dose intensity modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for treatment of high-risk prostate cancer. PATIENTS AND METHODS • Patients with high-risk prostate cancer were treated with a luteinising hormone-releasing hormone agonist (starting 2–3 months before IMRT and lasting 2 years), IMRT of 78 Gy to the prostate and seminal vesicles, and weekly docetaxel during RT. • All patients had computed tomography and bone scans to exclude metastatic disease. • A standard 3 + 3 design was used for docetaxel dose escalation. Successive patients were treated on dose levels of 10, 15, and 20 mg/m2 of weekly docetaxel. RESULTS • In all, 18 patients participated in the study: 15 (83%) had Gleason 8–10 disease; the other three had either clinical T3 disease and/or a prostate-specific antigen (PSA) level of >20 ng/mL. • Grade 3 diarrhoea (a defined dose-limiting toxicity, DLT) occurred in one patient in each of the first two dose levels. However, when the cohorts were expanded, no further DLT was seen. • Weekly docetaxel at 20 mg/m2 (dose level 3) was successfully given without DLT. • No patient had grade 4 or 5 toxicity. • At a median follow-up of 2.2 years, all patients achieved a PSA nadir of <1 ng/mL, including 13 patients who had an undetectable PSA level. The 2-year biochemical progression-free survival was 94%. CONCLUSION • A dose of 20 mg/m2 of weekly docetaxel given concurrently with high-dose IMRT and ADT appears safe for further study in patients with high-risk prostate cancer." @default.
- W1905903151 created "2016-06-24" @default.
- W1905903151 creator A5011907185 @default.
- W1905903151 creator A5012682914 @default.
- W1905903151 creator A5024126433 @default.
- W1905903151 creator A5027261067 @default.
- W1905903151 creator A5038459719 @default.
- W1905903151 creator A5041411617 @default.
- W1905903151 creator A5073387299 @default.
- W1905903151 creator A5075863856 @default.
- W1905903151 creator A5078699439 @default.
- W1905903151 creator A5082025794 @default.
- W1905903151 creator A5086661060 @default.
- W1905903151 creator A5086752243 @default.
- W1905903151 date "2012-09-27" @default.
- W1905903151 modified "2023-09-27" @default.
- W1905903151 title "Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer" @default.
- W1905903151 cites W1565276921 @default.
- W1905903151 cites W1901012653 @default.
- W1905903151 cites W1969753482 @default.
- W1905903151 cites W1975565006 @default.
- W1905903151 cites W1979665150 @default.
- W1905903151 cites W1985587689 @default.
- W1905903151 cites W1989206892 @default.
- W1905903151 cites W1996809772 @default.
- W1905903151 cites W2018909389 @default.
- W1905903151 cites W2035954427 @default.
- W1905903151 cites W2054899405 @default.
- W1905903151 cites W2062412101 @default.
- W1905903151 cites W2074421032 @default.
- W1905903151 cites W2079767901 @default.
- W1905903151 cites W2080439368 @default.
- W1905903151 cites W2088242641 @default.
- W1905903151 cites W2093867637 @default.
- W1905903151 cites W2117584600 @default.
- W1905903151 cites W2119991376 @default.
- W1905903151 cites W2120292596 @default.
- W1905903151 cites W2142114286 @default.
- W1905903151 cites W2146946216 @default.
- W1905903151 cites W2148539277 @default.
- W1905903151 cites W2169751580 @default.
- W1905903151 cites W76777577 @default.
- W1905903151 doi "https://doi.org/10.1111/j.1464-410x.2012.11536.x" @default.
- W1905903151 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23016517" @default.
- W1905903151 hasPublicationYear "2012" @default.
- W1905903151 type Work @default.
- W1905903151 sameAs 1905903151 @default.
- W1905903151 citedByCount "18" @default.
- W1905903151 countsByYear W19059031512013 @default.
- W1905903151 countsByYear W19059031512014 @default.
- W1905903151 countsByYear W19059031512015 @default.
- W1905903151 countsByYear W19059031512016 @default.
- W1905903151 countsByYear W19059031512017 @default.
- W1905903151 countsByYear W19059031512018 @default.
- W1905903151 countsByYear W19059031512019 @default.
- W1905903151 countsByYear W19059031512020 @default.
- W1905903151 countsByYear W19059031512022 @default.
- W1905903151 crossrefType "journal-article" @default.
- W1905903151 hasAuthorship W1905903151A5011907185 @default.
- W1905903151 hasAuthorship W1905903151A5012682914 @default.
- W1905903151 hasAuthorship W1905903151A5024126433 @default.
- W1905903151 hasAuthorship W1905903151A5027261067 @default.
- W1905903151 hasAuthorship W1905903151A5038459719 @default.
- W1905903151 hasAuthorship W1905903151A5041411617 @default.
- W1905903151 hasAuthorship W1905903151A5073387299 @default.
- W1905903151 hasAuthorship W1905903151A5075863856 @default.
- W1905903151 hasAuthorship W1905903151A5078699439 @default.
- W1905903151 hasAuthorship W1905903151A5082025794 @default.
- W1905903151 hasAuthorship W1905903151A5086661060 @default.
- W1905903151 hasAuthorship W1905903151A5086752243 @default.
- W1905903151 hasBestOaLocation W19059031511 @default.
- W1905903151 hasConcept C121608353 @default.
- W1905903151 hasConcept C126322002 @default.
- W1905903151 hasConcept C126894567 @default.
- W1905903151 hasConcept C143998085 @default.
- W1905903151 hasConcept C2776235491 @default.
- W1905903151 hasConcept C2776694085 @default.
- W1905903151 hasConcept C2777899217 @default.
- W1905903151 hasConcept C2780192828 @default.
- W1905903151 hasConcept C2781190966 @default.
- W1905903151 hasConcept C2781413609 @default.
- W1905903151 hasConcept C509974204 @default.
- W1905903151 hasConcept C71924100 @default.
- W1905903151 hasConceptScore W1905903151C121608353 @default.
- W1905903151 hasConceptScore W1905903151C126322002 @default.
- W1905903151 hasConceptScore W1905903151C126894567 @default.
- W1905903151 hasConceptScore W1905903151C143998085 @default.
- W1905903151 hasConceptScore W1905903151C2776235491 @default.
- W1905903151 hasConceptScore W1905903151C2776694085 @default.
- W1905903151 hasConceptScore W1905903151C2777899217 @default.
- W1905903151 hasConceptScore W1905903151C2780192828 @default.
- W1905903151 hasConceptScore W1905903151C2781190966 @default.
- W1905903151 hasConceptScore W1905903151C2781413609 @default.
- W1905903151 hasConceptScore W1905903151C509974204 @default.
- W1905903151 hasConceptScore W1905903151C71924100 @default.
- W1905903151 hasIssue "11b" @default.
- W1905903151 hasLocation W19059031511 @default.
- W1905903151 hasLocation W19059031512 @default.